Is MannKind Corporation (NASDAQ:MNKD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating MannKind Corporation at current levels.
Tyvaso DPI royalties fund an underappreciated orphan lung pipeline, with Afrezza pediatric data as the free call option.
Where MNKD is headed
MannKind in late 2027 looks nothing like the inhaled-insulin curiosity it was labelled as for a decade. The business today runs on two engines the market still prices as one. Tyvaso DPI royalties from United Therapeutics are compounding past $200M annually as the PH-ILD indication expands prescriber reach beyond specialist PAH centres into pulmonology practices that have never written a prostacyclin before. That royalty stream carries no COGS, no sales force, no marketing drag. It is the closest thing to a software margin a small-cap biotech will ever own, and it funds everything else.
Read the full Compass Direction on MNKD
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $3.42).
See the full MNKD analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is MannKind Corporation (NASDAQ:MNKD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating MannKind Corporation at current levels. Tyvaso DPI royalties fund an underappreciated orphan lung pipeline, with Afrezza pediatric data as the free call option.
What is MNKD's Compass Score?
MannKind Corporation scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for MNKD?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the MNKD page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.